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Abstract
Background: Cell transdifferentiation is characterized by loss of some phenotypes along with acquisition of new 
phenotypes in differentiated cells. The differentiated state of a given cell is not irreversible. It depends on the up- and 
downregulation exerted by specific molecules.
Results: We report here that HCCR-1, previously shown to play an oncogenic role in human cancers, induces epithelial-
to-mesenchymal transition (EMT) and mesenchymal-to-epithelial transition (MET) in human and mouse, respectively. 
The stem cell factor receptor CD117/c-Kit was induced in this transdifferentiated (EMT) sarcoma tissues. This MET 
occurring in HCCR-1 transfected cells is reminiscent of the transdifferentiation process during nephrogenesis. Indeed, 
expression of HCCR-1 was observed during the embryonic development of the kidney. This suggests that HCCR-1 might 
be involved in the transdifferentiation process of cancer stem cell.
Conclusions: Therefore, we propose that HCCR-1 may be a regulatory factor that stimulates morphogenesis of 
epithelia or mesenchyme during neoplastic transformation.
Background
The concept that genetic events cooperate to achieve
malignant transformation was proposed over a decade
ago. Primary rodent cells are efficiently converted into
tumorigenic cells by the co-expression of cooperating
oncogenes. However, similar experiments with human
cells have consistently failed [1]. In 1999, after more than
15 years of trying, researchers have managed to convert
normal human cells into tumor cells by delivering telom-
erase catalytic subunit in combination with two onco-
genes [2]. Although malignant transformation of human
cells by a single oncogene may not occur or may require
specialized factors, we demonstrated that HCCR-1, asso-
ciated with various types of human cancers, alone
induced tumorigenic conversion of mouse cells [3].
We have identified a novel oncogene, human cervical
cancer oncogene (HCCR), that was classified into 2 types:
HCCR-1 (GenBank accession number AF 195651) and
HCCR-2 (GenBank accession number AF 315598) [3].
The HCCR-1 and HCCR-2 overexpressed cells were tum-
origenic in nude mice and HCCR transgenic mice devel-
oped breast cancers and metastasis [3,4]. Also, HCCR-1
was overexpressed in various types of human malignan-
cies and was found to regulate the p53 tumor-suppressor
gene negatively [3-6]. However, it is unknown how
HCCR-1 contributes to the cellular and biochemical
mechanisms of human tumorigenesis.
Cell transdifferentiation is characterized by loss of
some phenotypesalong with acquisition of new pheno-
types in differentiated cells. Differentiated cells are
endowed with the capacity of transforming into cells of a
different type having other functions [7]. Gene expression
in differentiated cells has long been considered an irre-
versible phenomenon that is established at the time of
replication. Given that, although repressed, the same
genetic framework is present in all cell types, a change in
gene expression among differentiated cells was predict-
able in particular conditions.In fact, the differentiated
state of a given cell is not irreversible.It depends on the
up- and downregulation exerted by specificmolecules [8].
Recent research suggests that tumor formation may
result from the development of cancer stem cells by the
deregulation of normal self-renewal pathways of tissue
stem cells. Numerous signalling pathways have been
implicated in this process including Notch, Wnt, LIF (leu-
* Correspondence: jinwoo@catholic.ac.kr
1 Molecular Genetic Laboratory, Catholic Medical Research Institute, The 
Catholic University of Korea, Seoul, Korea
† Contributed equally
Full list of author information is available at the end of the article© 2010 Ha et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attri-
bution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any
medium, provided the original work is properly cited.
Ha et al. BMC Cell Biology 2010, 11:49
http://www.biomedcentral.com/1471-2121/11/49
Page 2 of 9kemia inhibitory factor), PTEN (phosphatase and tensin
homologue deleted from chromosome 10), SHH (sonic
hedgehog) and BMI1 [9-12]. The discovery of cancer
stem cells in AML, breast cancer and some CNS tumors
offers a new approach to understanding the biology of
these conditions. Further study into these and other
mechanisms controlling self-renewal pathways is needed
to understand not only what drives tumor formation
from cancer stem cells but also what mechanisms could
be used to 'switch off ' tumor formation [13].
We undertook this study with the following aims: 1) to
assess whether HCCR-1 overexpression converts normal
cells to malignant transformed cells; 2) to determine
whether HCCR-1 is involved in transdifferentiation pro-
cess and embryonic kidney development; 3) to examine
the molecular alterations occurring in HCCR-1 induced
tumorigenesis.
Results
HCCR-1 is involved in tumorigenesis and 
transdifferentiation
We investigated whether HCCR-1 alone can induce
malignant transformation of HEK-293 cells. Transfection
of HCCR-1 expression vector into HEK-293 cells yielded
a transformation efficiency (i.e., the number of foci per μg
of DNA transfected) of 0.9 (Table 1). The transformation
efficiency of the wild-type ras gene used as a positive
control was 1.2 (95% CI, 16.9-19.1) (Table 1). These data
suggest that HCCR-1 has almost as potent oncogenic
activity as wild-type ras in the HEK-293 assay system.
Comparable transfection with the control vector alone
(nontransformed 293 cells) yielded no transformation
(Table 1). In total, 20 of the transformed foci were iso-
lated from the HCCR-1 transfected 293 cells and were
grown in semisolid soft-agar medium to measure the col-
ony formation efficiency. HCCR-1-transfected 293 cells
formed colonies with an efficiency of 13%.
HEK-293 is a short spindle shaped cell having a bipolar
cell process (Figure 1A). Cultured 293 cells have similar
cytological features to cells transfected with vector alone
(Figure 1B). However, HCCR-1-transfected human 293
cells showed increase in cell size compared to wild-type
human 293 cells (Figure 1C). The cell processes were
blunted in HCCR-1-transfected human 293 cells. North-
ern blot showed that about 2.0-kilobase-pair mRNA tran-
script was over-expressed in all five HCCR-1-transfected
human 293 cells as compared with wild-type 293 cells
(Figure 1D). Nude mice injected with HCCR-1-trans-
fected human 293 cells showed palpable tumors in four
weeks. But cells transfected with vector alone did not
induce tumor formation in nude mice. Sections of the
nude mice tumor nodules bearing HCCR-1-transfected
human 293 cells revealed epithelial cell carcinomas (Fig-
ure 1E). Interestingly, however, the cells showed co-
expression of epithelial markers, such as cytokeratin 8
(Figure 1F) and cytokeratin 19 (Figure 1G), and of the
mesenchymal marker, vimentin that is normally
expressed by fibroblasts (Figure 1H). These results sug-
gest that transdifferentiation (EMT) occurred in HCCR-1
stably transfected 293 cells derived from nude mouse
tumors.
In order to confirm the above data, we performed the
immunofluorescence microscopy experiment in HEK-
293 and HEK-293 stable clone for HCCR-1 (Additional
file 1 Figure S1 A, B). The result showed that the parental
HEK-293 cells express the vimentin but in a lower level
than HCCR-1 stable HEK-293 clone. This suggests that
the vimentin level is slightly increased after HCCR-1
transfection. We then analyzed other epithelial markers
in HEK-293, HEK-293 clones stably transfected with
HCCR-1, and HEK-293 cells transfected with the empty
vector. E-cadherin, α-catenin, and β-catenin are essential
for the maintenance of epithelial structures. To deter-
mine whether the over-expression of HCCR-1 alters the
expression profiles of these molecules, we performed the
western blotting analyses as follows (Additional file 2 Fig-
ure S1 C). The result demonstrates that all of these epi-
thelial markers (E-cadherin, α-catenin, and β-catenin) are
down-regulated only in HCCR-1 stable cell lines. There-
fore, this data support that HCCR-1 induces EMT in
transformed HEK-293 cells.
Table 1: Transforming activity of HCCR-1 in HEK-293 cells
Transfected DNA source Foci/μg DNA* Transformation efficiency** 95% confidence intervals
HCCR-1 13/15 0.9 11.2-13.8
Wild-type ras 18/15 1.2 16.0-19.1
Vector alone 0/15 0 -
*HEK-293cells (3 × 105 cells) were transfected with 5 μg of DNA obtained from indicated source. The results reported here were derived from 
3 independent experiments.
**Transformed cell aggregates, foci, were counted by visual examination starting 2-3 weeks after transfection and the transformation 
efficiencies (i.e., the number of foci per microgram of DNA transfected) were determined.
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typically be expected to develop sarcomas because NIH/
3T3 cells are of mesenchymal origin [14]. However, the
tumors in nude mice derived from HCCR-1 stably trans-
fected NIH/3T3 cells had both sarcomatous (Figure 1I)
and epithelial features (Figure 1J). Histologically, the
tumors showed poorly differentiated sarcoma with epi-
thelial differentiation (carcinosarcoma) (Figure 1J). They
were composed mostly of spindle cells forming long and
short fasciles. In focal areas these cells were vaguely
aggregated to form epithelial cell nest-like structures
(arrows). Reticulin fibers enveloped individual spindle
cells in the sarcomatous areas, but enveloped vague epi-
thelial cell nests in the more carcinomatous areas (Figure
1K). For a morphologic comparison between HCCR-1-
derived tumor cells and epithelial cells, we determined
Figure 1 HCCR-1 is ivolved in tumorigenic conversion and transdifferentiation. Phase-contrast features of wild-type 293 cells (A), cells transfect-
ed vector alone (B) and HCCR-1-transfected human 293 cells (C). D. HCCR-1 mRNA expressions in HCCR-1-transfected human 293 cells (designated as 
clone A, B, C, D, and E, consecutively), and wild-type human 293 cells. E. Hematoxylin-eosin (H-E) staining of tumor nodules taken from the nude mice 
xenograft. The tumor cells show similar histological features with HCCR-1-transfected allografts. Tumor cells are arranged in nests separated by fine 
fibrovascular septae and have polygonal shape with oval nuclei, coarse chromatin and moderate amount of cytoplasm. Numerous mitotic figures are 
found. Immunohistochemical stainings of HCCR-1-transfected human 293 cells xenograft. Tumor cells show positive cytoplasmic stainings for cytok-
eratin 8 (F), cytokeratin 19 (G), and vimentin (H), respectively. Magnifications, E) × 300; F-H) × 250. Tumorigenic conversion and transdifferentiation 
of NIH/3T3 cells after transfection with HCCR-1. I and J. H-E staining of tumor nodules taken from nude mice after 3 weeks injection with HCCR-1-trans-
fected NIH/3T3 cells. [I, tumor sections show malignant spindle cell sarcoma; J, tumor sections show poorly differentiated sarcoma with focal epithelial 
differentiation (arrows)]. Magnification × 400. K. Reticulin stain was performed to detect reticulin fibers. Sections from the same tumor nodule were 
immunohistochemically stained with mouse monoclonal antibodies (DAKO) specific for epithelial membrane antigen (L), cytokeratin 7 (M), cytoker-
atin 8 (N), cytokeratin 19 (O), cytokeratin 20 (P), and vimentin (Q). DAB was used as the chromogen. After immunostaining, sections were counter-
stained with hematoxylin. Magnification × 200.
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lial cell markers, such as the epithelial membrane anti-
gens (Figure 1L), cytokeratin 7 (Figure 1M), cytokeratin 8
(Figure 1N), cytokeratin 19 (Figure 1O), cytokeratin 20
(Figure 1P), and the mesenchymal marker vimentin (Fig-
ure 1Q). HCCR-1-derived tumor cells were positive for
both epithelial and mesenchymal markers (Figures 1L-
1Q). These results suggest that transdifferentiation
(MET) occurred in HCCR-1 stably transfected NIH/3T3
cells derived from nude mice tumors. HCCR-1 might play
multiple developmental roles by mediating a signal origi-
nating from the mesenchyme and received by epithelia.
Mesenchymal signals are known to govern differentiation
and morphogenesis of many epithelia, but the molecular
nature of the signals is poorly understood. This expres-
sion pattern indicates that this mesenchymal factor can
transmit morphogenetic signals in epithelia development
and suggests a molecular mechanisim for mesenchymal
epithelial interactions. This study indicates that the
HCCR-1 oncogene may be a mesenchyme-derived
cytokine that stimulates the morphogenesis of epithelia
and mediates interactions between the mesenchyme and
epithelia during neoplasia.
Induction of c-kit proto-oncogene product by HCCR-1
CD117 (c-Kit) is a type III receptor tyrosine kinase oper-
ating in cell signal transduction in several cell types. Nor-
mally c-Kit is activated (phosphorylated) by binding of its
ligand, the stem cell factor (SCF) [15]. This leads to a
phosphorylation cascade ultimately activating various
transcription factors in different cell types. Such activa-
tion regulates apoptosis, cell differentiation, proliferation,
chemotaxis, and cell adhesion. Ligand independent acti-
vation of c-Kit (dysregulated kit function) has been found
to be an important component of oncogenesis in a large
number of neoplastic disorders such as systemic masto-
cytosis, germ cell tumors, acute myelogenous leukemia
(AML) with the disruption of the core binding factor,
amongst others [16]. C-Kit positivity has been variably
reported in sarcomas [16]. Among mesenchymal tumors,
c-kit seems to be specific for the gastrointestinal stromal
tumors (GISTs), which consistently express this protein.
These tumors uniformly express CD117, the c-Kit proto-
oncogene product [15]. Signal transductions from
tyrosine kinase receptors have key roles in the regulation
of cellular proliferation and differentiation [17] and bind-
ing of SCF to c-Kit activates multiple signal transduction
pathways, including phosphatidylinositol 3-kinase
(PI3K)/Akt [18]. Because HCCR-1 induced carcinosar-
coma and HCCR-1 is regulated by the PI3K/Akt signaling
pathway [19], we investigated whether HCCR-1-induced
nude mice-derived carcinosarcoma induces the expres-
sion of CD117, as does GIST. HCCR-1-derived tumor
cells showed a positive staining for CD117 (Figure 2A).
Western blot analysis also showed that NIH/3T3 cells sta-
bly transfected with HCCR-1 and nude mice-derived
tumors injected with NIH/3T3 cells transfected with
HCCR-1 both overexpressed the c-kit protein compared
with NIH/3T3 parental cells or cells transfected with vec-
tor alone (Figure 2B). Our study shows that HCCR-1-
derived tumor cells express CD117, suggesting that
HCCR-1 is related to the c-kit signaling pathway.
Embryonic kidney development
Co-expression of the human Met receptor, its ligand, and
hepatocyte growth factor/scatter factor (HGF/SF), in
NIH/3T3 fibroblasts causes cells to become tumorigenic
in nude mice. The resultant tumors display lumen-like
morphology, contain carcinoma-like focal areas with
intercellular junctions resembling desmosomes, and co-
express epithelial (cytokeratin) and mesenchymal
(vimentin) cytoskeletal markers. The apparent MET of
the tumor cells mimics the conversion that occurs during
embryonic kidney development, suggesting that Met-
HGF/SF signaling plays a role in this process as well as in
tumors that express both epithelial and mesenchymal
markers [20]. Because acquisition of epithelial properties
by the fibroblast-derived cells mimics the MET of cells
during the organogenesis of the kidney [20], we investi-
gated whether HCCR-1 is expressed in the developing
kidney. Immunoblot analysis demonstrated that as
probed by rabbit polyclonal anti-HCCR-1 serum, HCCR-
1 began to be overexpressed at fetal 18-day, remaining
high up to postnatal 14-day, and decreased to a very low
level in adult rat kidney (Additional file 2 Figure S2 A).
Sections of 20-day-old fetal rat kidney revealed that
HCCR-1 antibody stained throughout the collecting
ducts only (Additional file 1 Figure S2 B, medulla on the
left side), which are derived from the ureteric bud [21].
The developing nephrons in the cortex were not stained
(Additional file 1 Figure S2 B, nephrogenic zone on the
right side). But the basolateral plasma membranes of the
Figure 2 HCCR-1 induced the c-kit proto-oncogene product. 
HCCR-1 induced the c-kit proto-oncogene product. A. Sections were 
stained for CD117. B. Western blot analysis to determine the expres-
sion of c-kit proto-oncogene product. HCCR-1 gene in embryonic kid-
ney development.
Ha et al. BMC Cell Biology 2010, 11:49
http://www.biomedcentral.com/1471-2121/11/49
Page 5 of 9developing collecting duct, which are derived from the
ureteric bud, were especially reactive to HCCR-1 anti-
body (Additional file 1 Figure S2 C). Because nephrogen-
esis is stimulated by a distinct ureteric signal, diffusion-
limited basolateral molecules [22], which trigger MET, we
propose that the HCCR-1 product may be a mesen-
chyme-derived regulatory factor [23]that stimulates mor-
phogenesis of epithelia in the developmental process and
mediates interactions between mesenchyme and epithelia
during neoplastic transformation.
Molecular genetic alterations in the HCCR-1-induced 
tumorigenesis
In order to study whether there was an alteration in the
growth properties of HCCR-1-transfected cells, we exam-
ined cell cycle profiles. The percentage of wild-type NIH/
3T3 cells and HCCR-1-transfected cells in the S-phase
was 20.6% and 31.5%, respectively (Figure 3A, mid-log
phase). These results suggest that there was a significant
shift of the cell population out of the G 0/G 1-phase into
the S-phase in HCCR-1-transfected cells. To assess the
serum-dependent cell cycle progression, cells were cul-
tured in 0.5% bovine calf serum (BCS) for 36 hours. After
incubation, cells were released with 20% serum and har-
vested at the indicated times. In wild-type cells (mea-
sured at 0 hour), few cells remained in the S-phase (8%).
In contrast, a considerable number of HCCR-1-trans-
fected cells were still in the S-phase (21.8%), suggesting
that constitutive overexpression of HCCR-1 allowed for a
relative amount of resistance to serum deprivation-
induced G 0/G 1 arrest. Following the release of cells from
the growth arrest caused by serum-deprivation, there
were consistent increases of over 10% in the S-phase pop-
ulations of HCCR-1-transfected cells as compared to
wild-type cells at measured time intervals (24 hour and
48 hour, respectively). Therefore, overexpression of
HCCR-1 could deregulate cell growth by shortening the G
0/G 1-phase and increasing the S-phase population of
cells. It has been implicated that egr-1 functions as a
tumor-suppressor [24]. To assess whether HCCR-1-
induced tumor formation is associated with the loss of
egr-1 expression, we tested the time course of egr-1
expression. When quiescent cells were stimulated with
20% serum, a marked down-regulation of egr-1 was
observed in HCCR-1-transfected cells compared with
wild-type NIH/3T3 cells (Figure 3B). In contrast, upregu-
lation of GAPDH mRNA level in HCCR-1-transfected
cells was clearly seen, while no significant difference was
observed in the level of c-fos (Figure 3B). This result sug-
gests that down-regulation of tumor suppressor egr-1
may be involved in the tumor progression in HCCR-1-
overexpressing cells. To further explain the tumorigenesis
of HCCR-1, we determined the telomerase activity in
PKC-activated HCCR-1-transfected cells. Consistent
with a previous study [25],wild-type NIH/3T3 cells
showed detectable telomerase activity (Figure 3C). How-
ever, HCCR-1 gene transfection increased telomerase
activity up to about 7-fold when compared with wild-type
cells. Reports show that PKC induces a marked increase
in telomerase activity [26]. To determine whether the
increased telomerase activity in HCCR-1 transfected cells
is caused by PKC, a kinase assay was performed. PKC
activity of HCCR-1-transfected cells was increased by
about 10-fold when compared with wild-type cells (Fig-
ure 3D).
Discussion
The conversion of normal cells into tumor cells involves
changes in the activity of a number of distinct different
genes and proteins in a cell. Although researchers have
been able to transform normal mouse cells into tumor-
forming cells by introducing several cooperating onco-
genes into these cells, human cells have been resistant to
such transformation [8,27-29]. In this study, ectopic
expression of HCCR-1 alone results in direct tumorigenic
conversion of HEK-293 cells in vitro and in vivo.
Because NIH/3T3 cell is of mesenchymal origin
[14],sarcoma would typically develop from oncogene-
transformed NIH/3T3 [30]. But, nude mice bearing
HCCR-1 allograft display characteristics of epithelial car-
cinomas. Because acquisition of epithelial properties by
the fibroblast-derived cells mimics the mesenchymal to
epithelial conversion of cells during the organogenesis of
the kidney [20], we investigated whether HCCR-1 is
expressed in the developing kidney. The developing
nephrons in the cortex were not stained. But the basolat-
eral plasma membranes of the developing collecting duct,
which are derived from the ureteric bud [21],were espe-
cially reactive to HCCR-1 antibody. Because nephrogene-
sis is stimulated by a distinct ureteric signal, diffusion-
limited basolateral molecules [22],which trigger mesen-
chymal to epithelial conversion, we propose that the
HCCR-1 product may be a mesenchyme-derived regula-
tory factor [23]that stimulates morphogenesis of epithelia
in the developmental process and mediates interactions
between mesenchyme and epithelia during neoplastic
transformation. Our study suggests that overexpression
of HCCR-1 induces tumorigenesis, transdifferentiation
and embryonic kidney development.
Transdifferentiation is a change from one differentiated
phenotype to another involving morphological and func-
tional phenotypic markers [31,32]. The conversion of a
cell phenotype is likely to be accomplished by selective
enhancement of gene expression, which controls the ter-
minal developmental commitment of cells [33].There is
little known about 'master switch' genes that determine a
specific differentiation pathway and have the potential to
induce the process in a cell originally destined for a differ-
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Figure 3 Molecular alterations in HCCR-1-induced tumorigenesis. A. Cell-cycle profiles of wild-type NIH/3T3 cell and HCCR-1-transfected cells 
from a separate experiment. Exponentially growing cells were trypsinized and DNA content was determined by flow cytometry. To assess the serum-
dependent cell cycle progression, cells were cultured in 0.5% BCS for 36 houes. After incubation, cells were released with 20% serum and harvested. 
B. Tumor suppressor egr-1 expressions. HCCR-1-transfected cells were serum starved with 0.5% BCS for 36 hours, and then stimulated with fresh 20% 
serum. Total RNA was isolated, transferred, and hybridized with 32P-labeled egr-1, c-fos, and GAPDH probe, respectively. C. Determination of telom-
erase activity. Human telomerase-positive embryonic kidney 293 cells, 293 cell extracts treated with RNase (+ RNase), wild-type NIH/3T3, cells trans-
fected with vector alone and HCCR-1-transfected cells were analyzed by Telomerase PCR ELISA. Assays were performed according to the kit protocol 
with amounts of extracts equivalent to 1 ×10 3 cells. The telomerase activity in 293 cells, which served as a positive control, was abolished by pretreat-
ment with RNase. Results are the average mean absorbance values from four separate experiments (means and 95% confidence intervals) (wild-type 
versus HCCR-1, P < .05). D. Determination of PKC activity. Wild-type NIH/3T3, cells transfected with vector alone and HCCR-1-transfected cell extracts 
were prepared and assayed to determine PKC activity. Each value is the means and 95% confidence intervals of three independent experiments (wild-
type versus HCCR-1, P < 0.05).
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tiple developmental roles by mediating a signal
originating from the mesenchyme and received by epi-
thelia. Mesenchymal signals are known to govern differ-
entiation and morphogenesis of many epithelia, but the
molecular nature of the signals is poorly understood. This
expression pattern indicates that this mesenchymal factor
can transmit morphogenetic signals in epithelia develop-
ment and suggests a molecular mechanisim for mesen-
chymal epithelial interactions.
There is evidence to indicate that tumors develop sec-
ondarily to abnormalities in PKC-mediated signal trans-
duction [34].Reports show that PKC induces a marked
increase in telomerase activity [26].Besides tumor cells
typically have acquired damage to genes that directly reg-
ulate their cell cycles [35]. Our study suggests that dereg-
ulation of HCCR-1 activity in mouse NIH/3T3 cells might
result in the activation of PKC or telomerase, loss of par-
ticular cell cycle checkpoint controls, and downregula-
tion of tumor suppressor egr-1, thereby predisposing
NIH/3T3 cells to malignant conversion.
This present study suggests that HCCR-1 is an onco-
gene which induces the transformation of HEK293 and
NIH3T3 cells. Likewise, our previous study also demon-
strated that HCCR-1 is a mitochondrial out membrane
protein and suppresses the apoptosis [36]. Consistent
with this previous work, this study also reveals the anti-
apoptotic activity of HCCR-1 by reducing the expression
of Egr-1, a direct regulator of multiple tumor suppressors
including TGF beta1, PTEN, and p53. Therefore, both
studies support that HCCR-1 is an oncogene either by
suppressing apoptotic activities or by dysregulating Egr-
1, telomerase, or PKC activity. Since key functions related
to apoptosis or anti-apoptosis often occur in mitochon-
dria, it is not too surprising that HCCR-1 localizes to the
mitochondria.
Conclusions
In conclusion, we converted normal cells into tumor cells
by delivering HCCR-1 alone in combination with no
other oncogenes. EMT and MET occurred in HCCR-1-
transfected tumor cells. In addition, HCCR-1 participates
in induction of the c-kit proto-oncogene, in activation of
PKC and telomerase activities, and cell cycle progression.
While further studies are needed to characterize cellular
functions and regulatory mechanisms, HCCR-1 protein is
likely to be a candidate onco-developmental protein for
cancer stem cell in the development of human cancer.
Methods
Cell lines, construction of expression vector, and DNA 
transfection
Human embryonic kidney (HEK) 293 (ATCC CRL-1573)
and NIH/3T3 cells were obtained from the ATCC. HEK-
293/HCCR-1-V5 cell lineswere maintained in DMEM
(Gibco) containing 200 μg/ml G418, 10% FBS and 1%
PenStrep (Gibco).
Expression vector containing the coding region of
HCCR-1 was constructed as follows. First, the SalI frag-
ment was isolated from the prokaryotic expression vec-
tor, pCEV-LAC, which contains the entire HCCR-1
cDNA. Then, pcDNA3.1 (Invitrogen, CA) was digested
with XhoI to make a compatible end with SalI. A SalI
fragment containing the HCCR-1 coding sequence was
inserted into the XhoI-digested pcDNA3.1. Lipo-
fectamine (Gibco BRL, Rockville, MD) was used to intro-
duce the HCCR-1 expression vector into HEK-293 cells.
Morphology and tumorigenecity
Newly established cells grown in culture flasks were pho-
tographed by phase-contrast microscopy. To analyze
tumorigenecity, 5 ×10 6 cells were injected subcutane-
ously into the posterior lateral aspect of the trunk of mice
(5-week-old athymic nu/nu on BALB/c background).
Nude mice were sacrificed when the subcutaneous
tumors reached 1.5-2.5 cm in diameter.
Colony-forming efficiency
Five ×10 3 viable cells were suspended in 1 ml of 0.3%
noble agar (Difco Laboratories Inc., Detroit, MI) made
with complete media, and layered onto 0.6% agar in 35-
mm plates. All samples were plated in quadruplicate. The
number of cell colonies (>50 cells/cluster) was estimated
on days 21-28.
Immunoblot analysis and immunohistochemistry
For immunoblot analysis, cells were lysed in Laemmli
sample buffer. Proteins were separated by 10% SDS-
PAGE and then electroblotted. The membranes were
incubated with a rabbit polyclonal anti-HCCR-1 serum
and proteins were revealed by an ECL-Western blot
detection kit. We performed immunohistochemistry on
cryosections (5-μm) incubated with anti-vimentin, anti-
keratin, anti-EMA antibodies (DAKO), and polyclonal
antibody raised against HCCR-1. Binding of primary
antibody was visualized by biotinylated secondary anti-
body, avidin-horseradish peroxidase, and AEC as the
chromogen.
PKC and telomerase activity assays
PKC activity was measured using the SignaTECT™ Pro-
tein Kinase C Assay System (Promega, Madison, WI).
PKC activity was defined as the difference in counts per
minute incorporated into substrate in the absence and
presence of phospholipid. Telomerase activity was deter-
mined by using the telomerase PCR-ELISA kit (Boeh-
ringer Mannheim). Immortalized human kidney cells
(293 cells) provided in the kit were used as the positive
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cells by pretreatment with RNase.
Cell cycle experiments
Cells cultured at mid-log phase were growth arrested by
incubation in medium containing 0.5% bovine calf serum
for 36 hours. Cells to be analyzed for DNA content were
harvested following trypsinization, and fixed in 70% etha-
nol. Fixed cells were then stained with propidium iodide.
In brief, 50 μg/ml of propidium iodide staining solution
(Sigma) and 100 units per ml of RNase A (Boerhinger
Mannheim) were added to 2 ×10 6 cells. After incubation
for 1 hour, cellular DNA content was determined by fluo-
rescence analysis at 488 nm using a FACS Caliber (Becton
Dickinson). A minimum of 1 ×10 4 cells per sample was
analyzed with Modfit 5.2 software.
Statistical analysis
Data was analyzed by use of SAS software (SAS Institute,
Cary, NC). One-way analysis of variance was used for
comparing various outcome measures (e.g., PKC or
telomerase levels) in different experimental conditions.
The mean values and 95% confidence intervals for the
outcome variables are shown in relevant figures. All
reported P values are two-sided and were considered to
be statistically significant at the .05 level. P values for
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